Zynex (ZYXI) Lifted to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of Zynex (OTCMKTS:ZYXI) from a hold rating to a buy rating in a research note issued to investors on Saturday morning. Zacks Investment Research currently has $5.50 price target on the stock.

According to Zacks, “Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company’s product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company’s mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado. “

Get Zynex alerts:

ZYXI has been the subject of a number of other research reports. ValuEngine upgraded shares of Zynex from a hold rating to a buy rating in a report on Friday, February 8th. B. Riley reiterated a buy rating on shares of Zynex in a report on Friday, February 22nd.

ZYXI stock opened at $4.85 on Friday. Zynex has a one year low of $2.40 and a one year high of $5.90. The firm has a market capitalization of $161.51 million, a PE ratio of 22.05 and a beta of 1.05.

Zynex Company Profile

Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.

Recommended Story: How accurate is the Rule of 72?

Get a free copy of the Zacks research report on Zynex (ZYXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com